Equities Analysts Offer Predictions for BCYC FY2029 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - HC Wainwright upped their FY2029 earnings per share (EPS) estimates for Bicycle Therapeutics in a note issued to investors on Thursday, May 1st. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $1.22 per share for the year, up from their prior forecast of $1.20. HC Wainwright has a "Buy" rating and a $33.00 price objective on the stock. The consensus estimate for Bicycle Therapeutics' current full-year earnings is ($3.06) per share.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The firm had revenue of $9.98 million during the quarter, compared to analyst estimates of $8.67 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%.

BCYC has been the subject of several other research reports. Barclays dropped their price target on shares of Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. B. Riley decreased their price objective on Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. JMP Securities lowered their price objective on Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating for the company in a research report on Friday, May 2nd. Royal Bank of Canada reduced their target price on shares of Bicycle Therapeutics from $35.00 to $32.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Finally, Stephens reiterated an "equal weight" rating and set a $15.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $25.00.

Bicycle Therapeutics Trading Up 5.0 %

BCYC traded up $0.37 during trading hours on Monday, hitting $7.77. 659,852 shares of the company's stock were exchanged, compared to its average volume of 397,868. Bicycle Therapeutics has a 12-month low of $6.10 and a 12-month high of $28.67. The firm has a market cap of $537.70 million, a P/E ratio of -2.36 and a beta of 1.60. The firm has a 50 day moving average of $8.53 and a 200 day moving average of $14.09.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC grew its position in shares of Bicycle Therapeutics by 35.7% during the third quarter. Jane Street Group LLC now owns 20,180 shares of the company's stock worth $457,000 after acquiring an additional 5,310 shares during the last quarter. Geode Capital Management LLC grew its position in Bicycle Therapeutics by 79.3% during the 3rd quarter. Geode Capital Management LLC now owns 38,335 shares of the company's stock worth $868,000 after purchasing an additional 16,958 shares during the last quarter. Principal Financial Group Inc. acquired a new position in Bicycle Therapeutics in the third quarter valued at $10,028,000. JPMorgan Chase & Co. raised its holdings in shares of Bicycle Therapeutics by 26.8% in the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock valued at $191,000 after buying an additional 1,782 shares during the last quarter. Finally, Avior Wealth Management LLC acquired a new stake in shares of Bicycle Therapeutics during the fourth quarter worth about $57,000. Institutional investors and hedge funds own 86.15% of the company's stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.